The SFDA also renewed approval for Cephalosporin and Carbapenem antibiotics and liquid and lyophilised oncology drugs, after an extensive review and audit of the company's facilities.

Venus Remedies is a research and development driven global pharmaceutical company and among the leading injectable manufacturers in the world.

The company's consolidated net profit declined 41.8% to Rs 3.29 crore on 6% decrease in net sales to Rs 116.90 crore in Q3 FY23 over Q3 FY22.